Relaxin: Exploring the antifibrotic potential of a pregnancy hormone  by Gaedeke, Jens & Peters, Harm
Kidney International, Vol. 68 (2005), pp. 405–406
EDITORIAL
Relaxin: Exploring the antifibrotic potential of a
pregnancy hormone
Excess accumulation of extracellular matrix proteins
has been well recognized as a key feature of chronic kid-
ney diseases. Renal fibrosis, particularly tubulointersti-
tial fibrosis, parallels the progressive loss of organ func-
tion, which ultimately leads to overt renal failure and the
need for dialysis. Driven by distinct causes like hyper-
tension, chronic inflammation, elevated blood glucose,
or postrenal obstruction, development of kidney fibro-
sis is mediated and fine-tuned by a variety of cytokines,
growth factors, and soluble factors. Among others, trans-
forming growth factor-beta (TGF-b) is of pivotal im-
portance because of its ability to regulate both matrix
protein synthesis and degradation in a distinctive profi-
brotic manner. As the knowledge about TGF-b and
matrix protein biology and pathophysiology has substan-
tially increased over the recent years, new strategies to
tackle renal fibrosis have been developed that are cen-
tered around the cascade of TGF-b generation, TGF-b
signaling, and matrix protein deposition and degradation.
An emerging novel therapeutic approach to target fi-
brosis is relaxin, a small peptide hormone that is endoge-
nously produced by corpus luteum of the ovary. The name
relaxin is derived from its unique ability to soften con-
nective tissue of the reproductive tract in pregnancy (i.e.,
to relax the cervix and the pubic ligament to facilitate
delivery) [1]. Relaxin has received additional interest be-
cause it mediates the profound vascular effects seen in
pregnancy, too. The general hemodynamic changes and,
especially, the changes in renal hemodynamics in preg-
nancy (decline in renal vascular resistance, increase in
renal plasma flow and GFR) are mediated in large parts
by relaxin through actions on nitric oxide and endothe-
lin receptor B activation [1, 2]. Of particular interest to
nephrologists, relaxin blocks the renal hemodynamic ef-
fects of angiotensin II independently of pregnancy [3].
These vascular effects appear largely dependent on the
activation of matrix-metalloproteases (MMP), enzymes
that digest and remove collagens and other matrix pro-
teins [1, 2, 4]. Activation of MMPs by relaxin has been
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demonstrated in a large variety of cell types in vitro. Stud-
ies from relaxin knock-out mice have shown a marked
age-dependent fibrosis in nonreproductive organs such
as the kidney, heart, and lung [4, 5]. Administration
of recombinant relaxin has been documented to sub-
stantially reduce matrix accumulation in models of
pulmonary and liver fibrosis [1, 6]. In renal models, an-
tifibrotic and function-preserving effects of recombinant
relaxin were of a comparable magnitude as seen with
ACE inhibition [7]. In 12-month-old male relaxin knock-
out mice, a short-term relaxin treatment largely reduced
chronic renal collagen build-up, indicating regression of
established renal fibrosis [5]. Together, these studies show
a clear inhibitory effect of relaxin on tissue fibrosis, ex-
panding its role from a mere hemodynamic agent to
an important negative regulator of tissue matrix protein
content.
The study presented in this issue of Kidney Interna-
tional by Heeg et al [8] elegantly expands our current
knowledge of relaxin actions on renal matrix protein ac-
cumulation. Using human kidney fibroblasts, the authors
show that relaxin blocks TGF-b effects on matrix syn-
thesis and secretion, as well as the transformation of fi-
broblasts to myofibroblasts. Following a recurring theme
in relaxin biology, the secretion of matrix degrading en-
zymes (MMP-2 and MMP-9) was induced as well in hu-
man renal fibroblasts. Interestingly, the authors were able
to show that relaxin blocks the activation of Smad2, a
pivotal messenger of TGF-b effects, thus providing addi-
tional mechanistic data on relaxin effect on TGF-b that go
beyond MMPs. The use of well-characterized human re-
nal cell lines in this study provides encouraging evidence
that a lot of the beneficial effects of relaxin on TGF-b and
matrix protein biology are not only operative in rodent
disease models, but also in human cells. It clearly adds to
the recently published papers that provide exciting and
challenging new data on relaxin biology.
Recently, tissue binding sites for relaxin were identified
as the previous orphan leucine-rich guanine nucleotide-
binding receptors 7 and 8 (LGR-7 and LGR-8) [1, 2,
4]. LGR-7 is expressed in renal cells, and this raises the
question of a possible regulated expression in renal cells
in health and disease. Relaxin and TGF-b are poten-
tially engaged in a more complex interaction, as a recent
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report suggests that shows a down-regulation of the re-
laxin receptor after TGF-b treatment in human endome-
trial cells [9]. H3, a new member of the relaxin gene family,
has been described [4], which also engages with LGR-7.
Most intriguing is the discovery of local relaxin synthesis
in human tissues outside the reproductive tract. In hu-
man heart failure, there is cardiac relaxin synthesis, and
plasma relaxin levels are elevated proportionally to dis-
ease severity [10]. Furthermore, relaxin is supposedly ex-
pressed by rat and mouse kidneys, although definite data
have not been reported yet [2]. A lot of this work still
has to be studied in more detail, and to be expanded
into the field of renal disease, but the relaxin story is
somewhat reminiscent of that of other molecules whose
scope of action has gone from very limited roles to broad
involvement in multiple organs in health and disease.
Relaxin’s obvious inherent capacity to facilitate matrix
protein degradation and to regress established renal fi-
brosis deserves our further attention and research efforts.
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